Drug Profile

O3R 5671

Alternative Names: O3R-5671

Latest Information Update: 09 Oct 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Onco3R Therapeutics
Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Skin disorder therapies; Small molecules
Mechanism of Action Salt-inducible kinase 3 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Autoimmune disorders

Most Recent Events

06 Oct 2025 Pharmacokinetics and adverse events data from a phase I trial in Autoimmune disorders released by Onco3R Therapeutics
11 Sep 2025 Onco3R Therapeutics plans a first in human trial for Autoimmune disorders in Belgium (PO) in September 2025
04 Sep 2025 Preclinical trials in Autoimmune disorders in Belgium (PO) before September 2025

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com